4.7 Article

Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 19, Pages 8875-8894

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b01108

Keywords

-

Funding

  1. U.S. National Institutes of Health, NIH Director's Pioneer Award [DP1OD006933/DP1CA174419]
  2. Lustgarten Foundation Research Investigator Grant
  3. National Cancer Institute SPORE Grant in GI Cancer [5P50A095103-09]
  4. Vanderbilt Institute of Chemical Biology
  5. Vanderbilt Ingram Cancer Center [P30 CA68485]
  6. NIH SIG grant [I1S-10RR025677-01]
  7. Vanderbilt University
  8. U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]

Ask authors/readers for more resources

Son of sevenless homologue 1 (SOS1) is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS. In its active form, GTP-bound RAS is responsible for numerous critical cellular processes. Aberrant RAS activity is involved in similar to 30% of all human cancers; hence, SOS1 is an attractive therapeutic target for its role in modulating RAS activation. Here, we describe a new series of benzimidazole-derived SOS1 agonists. Using structure-guided design, we discovered small molecules that increase nucleotide exchange on RAS in vitro at submicromolar concentrations, bind to SOS1 with low double-digit nanomolar affinity, rapidly enhance cellular RAS-GTP levels, and invoke biphasic signaling changes in phosphorylation of ERK 1/2. These compounds represent the most potent series of SOS1 agonists reported to date.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available